Search results for "NATRIURETIC PEPTIDE"

showing 10 items of 178 documents

Abstract WP201: Stroke Patients With Atrial Fibrillation Detected by 72 hour- versus Prolonged ECG-monitoring

2018

Background: Detecting concealed paroxysmal atrial fibrillation (pAF) is a major focus in the workup of ischemic-stroke-patients. The minimal ECG-monitoring for stroke patients was recently expanded from 24 to 72 hours. However, it has been shown that even more prolonged monitoring reveals further pAF-cases. Our aim was to determine, whether known predictors for underlying pAF differ between stroke patients with AF that occurs on shorter (72h) or more prolonged ECG-monitoring (>72h). Methods: The Find-AF RANDOMISED -trial (NCT01855035) evaluated 3x10-day Holter-ECG vs. standard-care in patients > 60 years with acute ischemic strokes with the primary endpoint of novel pAF after 6 month…

Advanced and Specialized Nursingmedicine.medical_specialtyStroke patientmedicine.diagnostic_testbusiness.industrymedicine.drug_classParoxysmal atrial fibrillationAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseaseEcg monitoring03 medical and health sciences0302 clinical medicineInternal medicinemedicineNatriuretic peptideCardiologycardiovascular diseasesNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessElectrocardiographyStroke030217 neurology & neurosurgeryStroke
researchProduct

N-Terminal amino acid sequence analysis indicates that isolated atrial amyloid is derived from atrial natriuretic peptide

1988

Isolated atrial amyloid, the most frequent senile cardiac amyloid type, was chemically analysed. Amyloid fibrils obtained from a patient (NIP) were extracted and the predominant low-molecular-weight polypeptide (approximately 3.5 kDa, designated ASc2 NIP) was isolated by size exclusion high performance liquid chromatography in 60% formic acid. N-Terminal amino acid sequence analysis of this polypeptide was identical to that of the atrial natriuretic peptide alpha-hANP for the first 12 residues determined.

AmyloidAmyloidFormic acidMolecular Sequence DataSize-exclusion chromatographyIsolated atrial amyloidHigh-performance liquid chromatographyPathology and Forensic Medicinechemistry.chemical_compoundAtrial natriuretic peptidechemistryBiochemistrymental disordersHumansNIPFemaleAmino Acid SequencePeptide sequenceAtrial Natriuretic FactorAgedVirchows Archiv B Cell Pathology
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

The natriuretic system in human and murine submandibular salivary glands in health and disease: insights from head and neck tumour cases

2019

Introduction: The wide distribution of the atrial natriuretic peptide was paralleled by a similar presence of its receptors, an indication of the wide range of their biological effects beyond the control of the homeostatic process. This study depicts through immunohistochemical and molecular techniques the distribution and modulation of atrial natriuretic peptide and its receptors in human and murine salivary glands. It also highlights some clinical implications of ANP dysregulation. Methods: Human SMG’s tissue samples were biopsied from normal (3), people with benign (2) or with malignant tumors (8). In addition, biopsies were taken from normal mice (10). They were processed by standard me…

Atrial natriuretic factorAtrial natriuretic peptidemarker for oral carcinomaSubmandibular gland tumor
researchProduct

Atrial Natriuretic Peptide (ANP)-Presence in Human Inferior Turbinate after Treatment Botulinum Toxin Type A Treatment

2012

Atrial natriuretic peptidebusiness.industryMedicineGeneral MedicinePharmacologybusinessAfter treatmentBotulinum toxin typeResearch Journal of Biological Sciences
researchProduct

Involvement of prostacyclin and potassium channels in the diabetes-induced hyporeactivity of the rabbit carotid artery to B-type natriuretic peptide

2012

The relation between diabetes and stroke is bidirectional: diabetes is an important risk factor for ischemic stroke, and acute stroke frequently induces hyperglycemia. On the other hand, plasma B-type natriuretic peptide (BNP) levels are raised in diabetes and stroke. The purpose was to study how alloxan-induced diabetes might modify the effects of BNP in rabbit carotid arteries and the mechanisms involved in such actions. To do this, isometric tension in isolated rabbit carotid artery was recorded and prostanoids release and plasma NT-proBNP were measured by enzyme immunoassay. BNP induced a relaxation of phenylephrine-precontracted carotid arteries, and this relaxation was lower in diabet…

Blood GlucoseMalemedicine.medical_specialtyPotassium ChannelsEndotheliummedicine.drug_classProstacyclinNitric OxideGlibenclamideThromboxane A2chemistry.chemical_compoundDiabetes mellitusInternal medicineNatriuretic Peptide BrainDiabetes MellitusmedicineNatriuretic peptideAnimalscardiovascular diseasesEndothelial dysfunctionStrokePharmacologyDose-Response Relationship Drugbusiness.industryBody Weightmedicine.diseaseEpoprostenolPeptide FragmentsCarotid Arteriesmedicine.anatomical_structureEndocrinologychemistryPotassiumcardiovascular systemRabbitsbusinessReceptors Atrial Natriuretic Factorhormones hormone substitutes and hormone antagonistsmedicine.drugEuropean Journal of Pharmacology
researchProduct

Procalcitonin and long-term prognosis after an admission for acute heart failure

2014

Abstract Background Traditionally, procalcitonin (PCT) is considered a diagnostic marker of bacterial infections. However, slightly elevated levels of PCT have also been found in patients with heart failure. In this context, it has been suggested that PCT may serve as a proxy for underrecognized infection, endotoxemia, or heightened proinflammatory activity. Nevertheless, the clinical utility of PCT in this setting is scarce. We aimed to evaluate the association between PCT and the risk of long-term outcomes. Methods and results We measured at admission PCT of 261 consecutive patients admitted for acute heart failure (AHF) after excluding active infection. Cox and negative binomial regressi…

CalcitoninMalemedicine.medical_specialtyCalcitonin Gene-Related PeptideRenal functionHeart failurePatient ReadmissionProcalcitoninCohort StudiesRisk FactorsInternal medicineNatriuretic Peptide Brainparasitic diseasesInternal MedicineHumansMedicineIn patientLongitudinal StudiesProspective StudiesProtein PrecursorsIntensive care medicineAgedProportional Hazards ModelsAged 80 and overHeart Failurebusiness.industryDiagnostic markerBacterial InfectionsMiddle AgedPrognosisbacterial infections and mycosesmedicine.diseaseInflammatory biomarkersPeptide FragmentsEndotoxinsHospitalizationHeart failureAcute DiseaseCytokinesFemaleRisk of deathbusinessProcalcitoninBiomarkershormones hormone substitutes and hormone antagonistsEuropean Journal of Internal Medicine
researchProduct

Effects of sauna bath on heart failure : A systematic review and meta-analysis

2018

Background: Sauna bath has potential as a lifestyle treatment modality for heart failure (HF). It is important to analyze the current evidence to help suggest paths of future study and potential for clinical application. Hypothesis: Sauna bath has a positive effect on HF patients. Methods: PubMed, Cochrane Library, and CINAHL databases were searched to identify randomized and nonrandomized controlled studies to compare effects of sauna bath with no sauna bath. Studies were searched for both infrared sauna bath and Finnish sauna bath. The strength of evidence was rated using a modified GRADE approach. Out of 1444 studies, nine met the inclusion criteria and were included in this review. Seve…

Cardiac function curveMalemedicine.medical_specialtyInfrared Rayssaunominenheart failureReview030204 cardiovascular system & hematologyCochrane Librarysydämen vajaatoimintaVentricular Function LeftSteam Bath03 medical and health sciences0302 clinical medicineInternal medicineWaon therapyterveysvaikutuksetNatriuretic Peptide BrainmedicineInfrared saunaHumansCardiac and Cardiovascular Systems030212 general & internal medicineAgedHeart FailureEjection fractionKardiologiWaon therapybusiness.industrymeta-analyysiStroke VolumeGeneral Medicinearchitecture.styleRecovery of FunctionMiddle Agedmedicine.diseaseBlood pressureTreatment OutcomearchitectureHeart failureFinnish SaunaCardiologysydän- ja verisuonitauditsauna bathFemaleCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Iron overload does not potentiate doxorubicin induced cardiotoxicity in vivo in mice and in vitro in cardiomyocytes cell cultures

2013

Background: Doxorubicin (DOX), an anticancer anthracycline, is known to induce serious cardiotoxicity, which is believed to be mediated by oxidative stress and complex interactions with iron. However, the relations between iron metabolism and DOX-induced cardiotoxicity remain a matter of controversy. Methods: Firstly, we used an in vivo murine model of iron overloading (IO) where male C57BL/6 mice received during 3 weeks (D0-D20) a daily dextran-iron injection (15 mg/kg/day.) and then (D21) a single dose of 6 mg/kg DOX. We evaluated cardiac function with echocardiography, myocardial gene's expression, nitro-oxidative stress levels and iron status. Secondly, the anti-proliferative activity o…

Cardiac function curvemedicine.medical_specialtyCardiotoxicityAnthracyclinebusiness.industrymedicine.disease_causeEndocrinologyAtrial natriuretic peptideIn vivoInternal medicinepolycyclic compoundsmedicineDoxorubicinViability assayCardiology and Cardiovascular MedicinebusinessOxidative stressmedicine.drugEuropean Heart Journal
researchProduct

Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive r…

2011

Background— Diastolic dysfunction associated with high blood pressure (BP) leads to cardiac remodeling and fibrosis and progression to congestive heart failure. B-type natriuretic peptide (BNP) has BP-lowering, antifibrotic, and antihypertrophic properties, which makes BNP an attractive agent for attenuating the adverse cardiac remodeling associated with hypertension. In the current study, we tested the effects of sustained cardiac proBNP gene delivery on BP, cardiac function, and remodeling in spontaneously hypertensive rats (SHR). Methods and Results— We used the myocardium-tropic adeno-associated virus serotype 9 (AAV9) vector to achieve continuously enhanced cardiac rat proBNP expressi…

Cardiac function curvemedicine.medical_specialtymedicine.drug_classBNP; Natyriuretic peptides; hypertensive heart diseaseDiastolePhysiology (medical)Internal medicinemedicineNatriuretic peptideNatyriuretic peptidescardiovascular diseasesVentricular remodelingEjection fractionbusiness.industryheart failure natriuretic peptide hypertension.medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareHypertensive heart diseaseBlood pressureEndocrinologyHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesshypertensive heart diseasehormones hormone substitutes and hormone antagonistsBNP
researchProduct